Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Huth

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Clinical and Translational Science|May 26, 2022
Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agentsMatthias Hoch, Felix Huth, Masahiko Sato, et al.
Cancer Chemotherapy and Pharmacology|July 21, 2019
Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjectsVassilios Aslanis, Kenichi Umehara, Felix Huth, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 5, 2022
Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactionsHilmar Schiller, Felix Huth, Carole Schuhler, et al.
Clinical and Translational Science|August 25, 2021
Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modelingFelix Huth, Hilmar Schiller, Yi Jin, et al.
European Journal of Clinical Pharmacology|August 15, 2018
Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjectsAnne Gardin, Cathy Gray, Srikanth Neelakantham, et al.
Marine Biotechnology (New York, N.Y.)|February 13, 2004
Characterization of surfactin-like cyclic depsipeptides synthesized by Bacillus pumilus from ascidian Halocynthia aurantiumNatalie I Kalinovskaya, Tatyana A Kuznetsova, Elena P Ivanova, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 3, 2022
Time matters - <i>in vitro</i> cellular disposition kinetics help rationalizing cellular potency disconnectsBirk Poller, Sophie Werner, Norbert Domange, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 19, 2016
Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitorsKen-Ichi Umehara, Markus Zollinger, Elizabeth Kigondu, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|December 6, 2022
Novel insights into bile acid detoxification via CYP, UGT and SULT enzymesVlasia Kastrinou Lampou, Birk Poller, Felix Huth, et al.
Archives of Toxicology|November 14, 2024
Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanismsVlasia Kastrinou-Lampou, Raquel Rodríguez-Pérez, Birk Poller, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Clinical and Translational Science|May 26, 2022
Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agentsMatthias Hoch, Felix Huth, Masahiko Sato, et al.
Cancer Chemotherapy and Pharmacology|July 21, 2019
Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjectsVassilios Aslanis, Kenichi Umehara, Felix Huth, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 5, 2022
Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactionsHilmar Schiller, Felix Huth, Carole Schuhler, et al.
Clinical and Translational Science|August 25, 2021
Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modelingFelix Huth, Hilmar Schiller, Yi Jin, et al.
European Journal of Clinical Pharmacology|August 15, 2018
Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjectsAnne Gardin, Cathy Gray, Srikanth Neelakantham, et al.
Marine Biotechnology (New York, N.Y.)|February 13, 2004
Characterization of surfactin-like cyclic depsipeptides synthesized by Bacillus pumilus from ascidian Halocynthia aurantiumNatalie I Kalinovskaya, Tatyana A Kuznetsova, Elena P Ivanova, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 3, 2022
Time matters - <i>in vitro</i> cellular disposition kinetics help rationalizing cellular potency disconnectsBirk Poller, Sophie Werner, Norbert Domange, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 19, 2016
Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitorsKen-Ichi Umehara, Markus Zollinger, Elizabeth Kigondu, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|December 6, 2022
Novel insights into bile acid detoxification via CYP, UGT and SULT enzymesVlasia Kastrinou Lampou, Birk Poller, Felix Huth, et al.
Archives of Toxicology|November 14, 2024
Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanismsVlasia Kastrinou-Lampou, Raquel Rodríguez-Pérez, Birk Poller, et al.
Pageof 5